Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018357 | Respiratory Syncytial Virus Infections NIH | 0.33 |
| D014777 | Virus Diseases NIH | 0.11 |
| D003141 | Communicable Diseases NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
BACKGROUND Despite drastic quarantine measures, COVID-19 continues to propagate and threatens global healthcare systems by saturating their capacity with high transmissibility and the particularly protracted length of stay needed by those requiring intensive care. Indeed, once patients advance to the ICU, prognosis is poor and it is thus critical to test medications that may prevent complications and reduce viral shedding. i.e. to protect ambulatory patients and their families from complications and transmission and allow them to #StayHome. To date, no treatment has been reliably demonstrated as effective in COVID-19 patients. Hydroxychloroquine (HCQ), a common and well tolerated medication, has shown promise in vitro for reducing viral replication (for SARS-CoV-2 as well as other coronaviruses with pandemic potential such as SARS-CoV-1 and MERS). Since then, several small-scale hospital-based clinical studies have indicated the potential for reduced viral shedding and hospitalisation as well as favourable evolution of lung pathology. If started earlier, this treatment could prevent complications requiring hospitalisation and intensive care, which may not be available in low-income countries. Robust clinical trials are required to assess the potential of HCQ in COVID-19. OBJECTIVES This trial assesses the efficacy of early treatment with HCQ in COVID-19 outpatients to reduce the incidence and severity of complications including secondary hospitalisation, ICU admissions, lung pathology and death. Secondarily, this trial will also assess its efficacy to reduce viral transmission among household contacts during self-quarantine. The clinical data collected in this trial will also be critical in creating early prognostication models to better predict healthcare needs and have evidence-based prioritization of resource allocation, which is especially critical in low-resource settings. METHODS The trial will recruit 800 SARS-CoV-2+ patients and their household contacts at triage sites across Switzerland. Patients included are 1) at risk of poor outcome (comorbidities or >65y) and 2) well enough to self-isolate at home. These patients will be randomised 1:1 in HCQ:Placebo and given 6 days of early treatment (within 24 hours of the SARS-CoV-2 test). Intensive pragmatic multiparameter at-home follow-up (including point-of-care lung ultrasound in some sites) will continue until their outcome (resolution, or complications, such as hospitalisation, ICU admission, death). Household contacts will have before and after serological testing and social distancing knowledge and practices questionnaires to assess risk factors for infections. The household attack rate of new-onset infections can then assess the efficacy of HCQ to prevent transmission.
Description: Proportion of secondary hospitalisations (and their length), ICU admissions (and their length) and deaths.
Measure: Proportion of poor outcomes (in index cases) Time: During the period that the subject is considered as COVID-19-positive: Average of 11 daysDescription: Proportion of a household with new seropositivity for SARS-CoV-2
Measure: Secondary household attack rate (in household contacts) Time: From day 0 (diagnosis and enrolment of index case) to 14 days after the outcome of the index case is recorded (recovery, hospitalisation or death): Average of 25 daysDescription: An ordinal scale of disease severity using a visual analogue scale (0-10 where 0 is asymptomatic)
Measure: Subjective disease severity (in index cases) Time: During the period that the subject is considered as COVID-19-positive: Average of 11 daysDescription: As recorded during hospitalisation
Measure: Rate of acute respiratory distress syndrome (in index cases) Time: During the period that the subject is considered as COVID-19-positive: Average of 11 daysDescription: Measured with lung ultrasound, CT or x-ray
Measure: Severity of radiological lung pathology (in index cases) Time: During the period that the subject is considered as COVID-19-positive: Average of 11 daysDescription: An ordinal scale of disease severity using the evolution of clinical biomarkers such as oxygen saturation, respiration rate etc.
Measure: Objective disease severity (in index cases) Time: During the period that the subject is considered as COVID-19-positive: Average of 11 daysDescription: Plasma concentrations of HCQ measured by liquid chromatography-tandem mass spectrometry
Measure: Safety: Unintended toxic HCQ accumulation (in index cases) Time: During the period that the subject is considered as COVID-19-positive : Average of 11 daysDescription: Ambulatory ECG and intensive monitoring for adverse events
Measure: Safety: Adverse events (in index cases) Time: During the period that the subject is considered as COVID-19-positive : Average of 11 daysDescription: Visual analogue scores for social distancing practices (0-5, where 0 is no social distancing at all)
Measure: Social distancing knowledge, attitudes and practices amongst index cases and household contacts Time: During the period that the subject is considered as COVID-19-positive: Average of 11 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports